Automatic Speech Recognition for speech therapy in a Parkinson’s disease patient
Objective: The aim of the present study was to examine the Automatic Speech Recognition (ASR) technology as a useful approach to enhance the speech intelligibility…Longitudinal assessment of quality of life in early Parkinson’s disease: 5-year follow up study
Objective: To determine changes in HR-QoL in early PD patients during a 5-year follow up period. Background: There is limited evidence on longitudinal changes in…Lentiform fork sign and Wilson Disease
Objective: First description of lentiform fork sign in patients with the diagnosis of Wilson disease. Background: Lentiform fork sign is a rare neuroradiological sign characterized…Effects of Once-Daily Opicapone 50 mg on COMT activity: A Pooled Post-hoc Analysis of Two Phase 1 Studies
Objective: To assess the effects of opicapone (OPC) 50 mg adjunct to carbidopa/levodopa (CD/LD) on catechol-O-methyltransferase (COMT) activity by participants’ baseline characteristics using pooled data…Impact of COVID-19 in Parkinson disease: preliminary analysis from a survey performed in a Peruvian PD cohort.
Objective: To analyze the impact of COVID-19 in Parkinson cases and healthy controls from a Peruvian population. Background: The COVID-19 pandemic have a profound impact…Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease
Objective: In this study, we investigated the effects of SR9009, a Rev-ERB agonist, on the dopaminergic system in the MPTP model of PD. Background: Circadian…Prevalence of sleep disorders symptoms in essential tremor
Objective: The aim is to study the prevalence of sleep disorders symptoms in patients with essential tremor (ET). Background: ET is the most common movement…NUS1 Mutation Causing Ataxia, Myoclonus, and Progressive Encephalopathy
Objective: Describe a rare cause of progressive myoclonus, ataxia, developmental delay Background: 37-year-old man with normal birth but delays in developmental milestones presented for evaluation…Level of glial neurotrophic factor in the blood plasma depending on the duration of Parkinson’s disease
Objective: To study the level of glial neurotrophic factor in the blood plasma depending on the duration of PD. Background: Study of the biochemical aspects…IncobotulinumtoxinA for treating chronic sialorrhea due to Parkinson’s disease and other neurological conditions
Objective: To summarize clinical experience with incobotulinumtoxinA (INCO) for treating chronic sialorrhea due to Parkinson’s disease (PD), atypical parkinsonism, stroke, or traumatic brain injury in…
- « Previous Page
- 1
- …
- 125
- 126
- 127
- 128
- 129
- …
- 153
- Next Page »